Anja Verhulst
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anja Verhulst has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Ellen Neven
Laboratory of Pathophysiology, Department of Biomedical Sciences, University of Antwerp, 2000 Antwerpen, Belgium
2 shared publications Marc E. De Broe
2 shared publicationsPatrick D'Haese
Laboratory of Pathophysiology, University of Antwerp, Wilrijk, Belgium
2 shared publicationsAbdelkrim Azmi
Biomedical Sciences, University of Antwerp, Wilrijk, Belgium
1 shared publicationAnnelies De Beuf
1 shared publicationAnnelies De Maré
Laboratory of Pathophysiology, University of Antwerp, Wilrijk, Belgium
1 shared publication
Latest Publications
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i132
FP299EFFECT OF SUCROFERRIC OXYHYDROXIDE (PA21) ON RENAL FUNCTION, MINERAL HOMEOSTASIS AND VASCULAR CALCIFICATION IN A RAT MODEL WITH CHRONIC KIDNEY DISEASE (CKD)
INTRODUCTION AND AIMS: PA21 (or sucroferric oxyhydroxide) is an iron-based phosphate binding agent and a promising alternative to existing compounds. Clinical trials have shown that PA21 is an efficacious and well-tolerated phosphate binder. We aimed to evaluate the effect of this iron-based phosphate binding agent on renal function, mineral homeostasis and vascular calcification in a rat model with adenine-induced CKD and vascular calcifications.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i132
FP299EFFECT OF SUCROFERRIC OXYHYDROXIDE (PA21) ON RENAL FUNCTION, MINERAL HOMEOSTASIS AND VASCULAR CALCIFICATION IN A RAT MODEL WITH CHRONIC KIDNEY DISEASE (CKD)
INTRODUCTION AND AIMS: PA21 (or sucroferric oxyhydroxide) is an iron-based phosphate binding agent and a promising alternative to existing compounds. Clinical trials have shown that PA21 is an efficacious and well-tolerated phosphate binder. We aimed to evaluate the effect of this iron-based phosphate binding agent on renal function, mineral homeostasis and vascular calcification in a rat model with adenine-induced CKD and vascular calcifications.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i617
SuO003INDOXYL SULFATE AND P-CRESYL SULFATE PROMOTE VASCULAR CALCIFICATION BY GLUCOSE MEDIATED ACTIVATION OF INFLAMMATION AND COAGULATION PATHWAYS
INTRODUCTION AND AIMS: Protein-bound uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (PCS) have been associated with cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). We aimed to provide direct evidence for a role of these toxins in CKD-related vascular calcification.
- 1 May 2018
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 33 (suppl_1) , i617
SuO003INDOXYL SULFATE AND P-CRESYL SULFATE PROMOTE VASCULAR CALCIFICATION BY GLUCOSE MEDIATED ACTIVATION OF INFLAMMATION AND COAGULATION PATHWAYS
INTRODUCTION AND AIMS: Protein-bound uremic toxins indoxyl sulfate (IS) and p-cresyl sulfate (PCS) have been associated with cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD). We aimed to provide direct evidence for a role of these toxins in CKD-related vascular calcification.
- Open Access
- 12 August 2011
- Published by S. Karger AG in Nephron Extra
- Vol. 1 (1) , 24-37
Low Doses of Cadmium Chloride and Methallothionein-1-Bound Cadmium Display Different Accumulation Kinetics and Induce Different Genes in Cells of the Human Nephron
Background/Aims: The present study was conducted to investigate the renal tubular handling of inorganic cadmium (Cd2+) by exposing primary human tubular cell cultures to physiologically relevant doses of cadmium chloride (CdCl2). Furthermore, the cellular accumulation of Cd2+ was compared to that of metallothionein-1-bound Cd (Cd7MT-1). Finally, this study aimed to investigate the effect of the accumulation of Cd (both Cd2+ and Cd7MT-1) in renal cells on the expression of genes relevant to nephrotoxic processes. Methods: Cd concentration was measured using atomic absorption spectrometry. mRNA expression was evaluated by quantitative real-time RT-PCR. Results: Cd2+ accumulated into human tubular cells in a concentration- and time-dependent way. Furthermore, cellular accumulation of Cd2+ was different from the cellular accumulation of Cd7MT-1, indicative for different uptake routes. Finally, mRNA expression of the genes encoding the anti-oxidative proteins metallothionein-1 (MT-1) and heme-oxygenase-1 (HO-1) as well as the pro-apoptotic Bcl-2-associated X protein (Bax) were upregulated by CdCl2 and not by Cd7MT1. Conclusion: In the presence of physiologically relevant Cd concentrations, tubular accumulation of the element in its inorganic form is different from that of Cd7MT-1. Furthermore, the tubular accumulation of inorganic Cd induces mRNA expression of genes of which the protein products may play a role in Cd-associated renal toxicity.
- 12 August 2011
- Published by S. Karger AG in Nephron Extra
- Vol. 1 (1) , 24-37
Open AccessLow Doses of Cadmium Chloride and Methallothionein-1-Bound Cadmium Display Different Accumulation Kinetics and Induce Different Genes in Cells of the Human Nephron
Background/Aims: The present study was conducted to investigate the renal tubular handling of inorganic cadmium (Cd2+) by exposing primary human tubular cell cultures to physiologically relevant doses of cadmium chloride (CdCl2). Furthermore, the cellular accumulation of Cd2+ was compared to that of metallothionein-1-bound Cd (Cd7MT-1). Finally, this study aimed to investigate the effect of the accumulation of Cd (both Cd2+ and Cd7MT-1) in renal cells on the expression of genes relevant to nephrotoxic processes. Methods: Cd concentration was measured using atomic absorption spectrometry. mRNA expression was evaluated by quantitative real-time RT-PCR. Results: Cd2+ accumulated into human tubular cells in a concentration- and time-dependent way. Furthermore, cellular accumulation of Cd2+ was different from the cellular accumulation of Cd7MT-1, indicative for different uptake routes. Finally, mRNA expression of the genes encoding the anti-oxidative proteins metallothionein-1 (MT-1) and heme-oxygenase-1 (HO-1) as well as the pro-apoptotic Bcl-2-associated X protein (Bax) were upregulated by CdCl2 and not by Cd7MT1. Conclusion: In the presence of physiologically relevant Cd concentrations, tubular accumulation of the element in its inorganic form is different from that of Cd7MT-1. Furthermore, the tubular accumulation of inorganic Cd induces mRNA expression of genes of which the protein products may play a role in Cd-associated renal toxicity.
- 2 August 2010
- Published by Springer Nature in Urological Research
- Vol. 38 (4) , 249-256
The tubular epithelium in the initiation and course of intratubular nephrocalcinosis
Intratubular nephrocalcinosis is defined as the histological observation of calcium oxalate and/or calcium phosphate deposits retained within the lumen of the renal tubules. As the tubular epithelium is the primary interaction partner of crystals formed in the tubular fluid, the role of the epithelial cells in nephrocalcinosis has been investigated intensively. This review summarizes our current understanding on how the tubular epithelium mechanistically appears to be involved both in the initiation and in the course of nephrocalcinosis, with emphasis on in vivo observations.
- 2 August 2010
- Published by Springer Nature in Urological Research
- Vol. 38 (4) , 249-256
The tubular epithelium in the initiation and course of intratubular nephrocalcinosis
Intratubular nephrocalcinosis is defined as the histological observation of calcium oxalate and/or calcium phosphate deposits retained within the lumen of the renal tubules. As the tubular epithelium is the primary interaction partner of crystals formed in the tubular fluid, the role of the epithelial cells in nephrocalcinosis has been investigated intensively. This review summarizes our current understanding on how the tubular epithelium mechanistically appears to be involved both in the initiation and in the course of nephrocalcinosis, with emphasis on in vivo observations.
- Open Access
- 1 October 2008
- Published by Elsevier in Molecular Pharmacology
- Vol. 74 (4) , 1084-1091
Human Proximal Tubular Epithelium Actively Secretes but Does Not Retain Rosuvastatin
Rosuvastatin is a potent HMG-CoA reductase inhibitor that has proven to be effective in the treatment of dyslipidemia. Rosuvastatin is cleared from the body by both biliary and renal clearance, the latter believed to be due to active tubular secretion. Whereas the mechanisms of hepatic clearance of rosuvastatin are well documented, those of renal clearance are not. Because rosuvastatin (and other statins) may alter proximal tubular function, this study aimed to characterize the mechanisms of tubular rosuvastatin secretion to define the factors that could influence the presence/concentration of rosuvastatin in proximal tubular cells. Hereto, polarized monolayers of primary human tubular cells were used. We found rosuvastatin net secretion across proximal tubule cells, which was saturable (K50 = 20.4 ± 4.1 μM). The basolateral uptake step was rate-limiting and mediated by OAT3. Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. These data, obtained in an intact human tubule cell model, provide a detailed insight into rosuvastatin's renal handling and the possible factors influencing it.
- 1 October 2008
- Published by Elsevier in Molecular Pharmacology
- Vol. 74 (4) , 1084-1091
Open AccessHuman Proximal Tubular Epithelium Actively Secretes but Does Not Retain Rosuvastatin
Rosuvastatin is a potent HMG-CoA reductase inhibitor that has proven to be effective in the treatment of dyslipidemia. Rosuvastatin is cleared from the body by both biliary and renal clearance, the latter believed to be due to active tubular secretion. Whereas the mechanisms of hepatic clearance of rosuvastatin are well documented, those of renal clearance are not. Because rosuvastatin (and other statins) may alter proximal tubular function, this study aimed to characterize the mechanisms of tubular rosuvastatin secretion to define the factors that could influence the presence/concentration of rosuvastatin in proximal tubular cells. Hereto, polarized monolayers of primary human tubular cells were used. We found rosuvastatin net secretion across proximal tubule cells, which was saturable (K50 = 20.4 ± 4.1 μM). The basolateral uptake step was rate-limiting and mediated by OAT3. Rosuvastatin efflux at the apical membrane was mediated by MRP2/4 and ABCG2 together with a small contribution from MDR1 or P-glycoprotein. These data, obtained in an intact human tubule cell model, provide a detailed insight into rosuvastatin's renal handling and the possible factors influencing it.
- 1 July 2007
- Published by Elsevier in Kidney International
- Vol. 72 (1) , 13-18
Proposed mechanisms in renal tubular crystal retention
- 1 July 2007
- Published by Elsevier in Kidney International
- Vol. 72 (1) , 13-18
Proposed mechanisms in renal tubular crystal retention
- Open Access
- 12 April 2002
- Published by Hindawi Limited
SYNTHESIS, SECRETION AND LOCALIZATION OF OSTEOPONTIN IN THE HUMAN NEPHRON
- 12 April 2002
- Published by Hindawi Limited
Open AccessSYNTHESIS, SECRETION AND LOCALIZATION OF OSTEOPONTIN IN THE HUMAN NEPHRON